US20040121313A1 - Methods for rapid detection and identification of bioagents in organs for transplantation - Google Patents

Methods for rapid detection and identification of bioagents in organs for transplantation Download PDF

Info

Publication number
US20040121313A1
US20040121313A1 US10/326,051 US32605102A US2004121313A1 US 20040121313 A1 US20040121313 A1 US 20040121313A1 US 32605102 A US32605102 A US 32605102A US 2004121313 A1 US2004121313 A1 US 2004121313A1
Authority
US
United States
Prior art keywords
method
nucleic acid
bioagent
base
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/326,051
Inventor
David Ecker
Richard Griffey
Rangarajan Sampath
Steven Hofstadler
John McNeil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ibis Biosciences Inc
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US43131902P priority Critical
Priority to US10/323,233 priority patent/US20040121309A1/en
Priority to US10/326,051 priority patent/US20040121313A1/en
Priority to US10/325,526 priority patent/US20040121311A1/en
Priority to US10/325,527 priority patent/US20040121335A1/en
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Priority to US44344303P priority
Priority to US44378803P priority
Priority to US44752903P priority
Assigned to ISIS PHARMACEUTICALS, INC. reassignment ISIS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ECKER, DAVID J., GRIFFEY, RICHARD H., HOFSTADLER, STEVEN A., MCNEIL, JOHN, SAMPATH, RANGARAJAN
Priority to US10/660,122 priority patent/US7781162B2/en
Priority claimed from AU2003298030A external-priority patent/AU2003298030B2/en
Priority claimed from AU2003297687A external-priority patent/AU2003297687B2/en
Priority claimed from JP2005508560A external-priority patent/JP2006516193A/en
Priority claimed from US10/728,486 external-priority patent/US7718354B2/en
Publication of US20040121313A1 publication Critical patent/US20040121313A1/en
Assigned to IBIS BIOSCIENCES, INC. reassignment IBIS BIOSCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ISIS PHARMACEUTICALS, INC.
Application status is Abandoned legal-status Critical

Links